-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16

Benzinga·10/20/2026 18:12:35
Listen to the news
Oppenheimer analyst Mazahir Alimohamed maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $22 to $16.